MSB News: Mesoblast Key Opinion Leader Event Series for Investors & Analysts - 9th Jun 2022, 9:00pm

annb0t

Top 20
Mesoblast Limited

Chronic Low Back Pain due to Degenerative Disc Disease

NEW YORK, June 09, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webinar focused on the current treatment landscape and unmet medical need for patients with chronic low back pain (CLBP) due to degenerative disc disease, a condition associated with local inflammation in the disc. The webinar will feature presentations...

>>> Read more: Mesoblast Key Opinion Leader Event Series for Investors & Analysts
 
Top Bottom